Pancreatic cystic lesions — evaluation & surveillance
Pancreatic cyst · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Increasingly found incidentally; management separates benign serous cysts from mucinous (IPMN, MCN) lesions with malignant potential. Worrisome/high-risk features direct EUS, resection or structured surveillance.
Red flags
- Obstructive jaundice
- Enhancing mural nodule or solid component
- Main pancreatic duct dilatation ≥10 mm
- New-onset diabetes or weight loss
- Rapid cyst growth
Assessment
Differential diagnosis
- Intraductal papillary mucinous neoplasm (IPMN, main vs branch duct)
- Mucinous cystic neoplasm (MCN)
- Serous cystadenoma (benign)
- Pseudocyst (post-pancreatitis)
- Cystic degeneration of solid tumour (NET, adenocarcinoma)
- Solid pseudopapillary neoplasm
Investigations
- Pancreatic-protocol MRI/MRCP (characterise, ductal communication)
- Contrast CT if MRI unavailable
- EUS with fine-needle aspiration (cyst fluid CEA, amylase, cytology, molecular)
- CA19-9 if concern
- Review prior imaging for growth
Management
- Characterise the cyst with MRI/MRCP and determine ductal communication and morphology
- Identify high-risk stigmata: obstructive jaundice, enhancing mural nodule ≥5 mm, main duct ≥10 mm
- Identify worrisome features: size ≥3 cm, thickened walls, non-enhancing nodule, duct 5–9 mm, abrupt duct change, lymphadenopathy, raised CA19-9
- Exclude pseudocyst by history (prior pancreatitis) and fluid amylase
- Perform EUS-FNA where features are worrisome or diagnosis unclear (high cyst CEA suggests mucinous)
- Refer lesions with high-risk stigmata or main-duct IPMN for surgical resection assessment
- Enter branch-duct IPMN/MCN without worrisome features into size-based surveillance
- Surveillance interval by size: smaller cysts less frequently, larger cysts more frequently
- Surgically manage mucinous cystic neoplasms in surgically fit patients
- Escalate to EUS/resection if new worrisome features or growth develop
- Discuss all concerning lesions at a pancreatic MDT
Drugs & doses
No specific pharmacotherapy — management is surveillance versus surgery
Disposition
Pancreatic MDT; surgical referral for high-risk lesions, structured radiology surveillance otherwise.
Complications & pitfalls
- Progression to pancreatic adenocarcinoma (mucinous lesions)
- Acute pancreatitis from ductal obstruction
- Surgical morbidity if resected
- Missed malignancy with inadequate follow-up
Exam pearls
- Serous cystadenomas are benign; mucinous lesions (IPMN, MCN) carry malignant potential and drive management
- Main-duct IPMN has high malignant potential and usually warrants resection in fit patients
- High cyst-fluid CEA suggests a mucinous lesion; high amylase suggests ductal communication/pseudocyst
- A prior episode of pancreatitis makes a pseudocyst far more likely than a neoplasm
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.